arrow
F

Fernando López-Campos

European University of Madrid
H指数:17
被引数:1,337

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early adverse events and patient-reported outcomes after salvage radiotherapy following prostatectomy according to fractionation schedule: Interim analysis of the phase III URONCOR 06-24 trial

根据分割方案进行前列腺切除术后挽救性放疗的早期不良事件和患者报告结局:URONCOR 06-24 III期试验的期中分析

2026-09-010
PRE
Whole-pelvic Versus Prostate-only Radiotherapy in Clinically Node-negative High-Risk Localised Prostate Cancer: A Systematic Review and Meta-analysis with Reconstructed Individual-patient Data

临床N0期局部高危前列腺癌全盆腔与前列腺单放治疗的系统评价与基于重建个体患者数据的Meta分析

2026-09-010
PRE
MRI-guided adaptive stereotactic body radiotherapy for the prostate bed: a prospective study of safety, tolerability, and patient-reported quality-of-life outcomes

MRI引导的自适应前列腺床立体定向体部放射治疗:一项关于安全性、耐受性及患者报告生活质量结局的前瞻性研究

2026-07-010
PRE
Early outcomes of online adaptive MR-guided SBRT for localized prostate cancer: a prospective study

局部前列腺癌在线自适应MR引导SBRT的早期结果:一项前瞻性研究

2026-07-010
PRE
Androgen receptor pathway inhibitor intensification in non-metastatic hormone-sensitive prostate cancer: current evidence and clinical implications

雄激素受体通路抑制剂强化治疗在非转移性激素敏感性前列腺癌中的应用:当前证据及临床意义

2026-04-100
PRE
Long-Term Results of a Propensity Score Analysis Comparing 5 × 5 Gy and 10 × 3 Gy of Radiotherapy Alone for Malignant Spinal Cord Compression

倾向性评分分析比较5×5 Gy和10×3 Gy单用放射治疗恶性脊柱 cord compression的长期结果

2025-12-100
OAAI
Management of high-risk prostate cancer in Spain: results from a national patterns of care survey

西班牙高风险前列腺癌的管理:国家医疗模式调查结果

2025-10-290
PRE
Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations

优化前列腺癌患者管理的治疗联盟:SOGUG多学科专家小组建议

2025-10-010
OAAI
Efficacy and safety of rechallenge therapy with [177Lu]Lu-PSMA in metastatic castration-resistant prostate cancer: a systematic review and meta-analysis

[177Lu]Lu-PSMA在转移性去势抵抗性前列腺癌中再挑战治疗的有效性与安全性:一项系统评价和荟萃分析

2025-07-240
OAAI
Drug-drug interactions in metastatic hormone-sensitive prostate cancer (mHSPC): practical considerations for treating men with androgen receptor pathway inhibitors and common medications in this stage

转移性激素敏感性前列腺癌 (mHSPC) 的药物-药物相互作用: 在此阶段使用雄激素受体途径抑制剂和常用药物治疗男性的实际考虑

2025-03-010
OA
Multi-institutional Analysis of Metastasis-directed Therapy with or Without Androgen Deprivation Therapy in Oligometastatic Castration-sensitive Prostate Cancer

寡转移去势敏感性前列腺癌转移导向治疗联合或不联合雄激素阻断治疗的多机构分析

2024-12-010
OA
A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532)
2024-10-011
OA
A Phase II Trial of Stereotactic Body Radiation Therapy and Androgen Deprivation for Oligometastases in Prostate Cancer (SBRT-SG 05)
2024-09-014
PRE
A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24

根治性前列腺切除术后生化失败的短期和长期雄激素剥夺与挽救性放疗的随机试验: URONCOR 06-24

2024-07-231
PRE